Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Clinical trial NCT06058377 · RECRUITING

Trial details

NCT number: NCT06058377
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 HER2-Negative Breast Carcinoma Hormone Receptor-Positive Breast Carcinoma

Start date: 2023-11-27
Primary completion: 2032-05-31
Enrollment: 3680

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.